Comparing expression levels of hnRNPA2/B1 in non-cancerous, patient-derived skin samples from the GTEx database (n = 1,305 patient tissues) versus in NRAS- or BRAF-mutated melanoma tumors from the TCGA database (n = 366 patient tissues), we found that hnRNPA2/B1 is significantly more expressed in MAPK-driven melanoma (Fig. 5h; p < 0.001). This evidence concerns the gene BRAF and melanoma.